Autolus to Present Obe-cel Data Showing 59% Response Rate, 42.6-Month DOR
AUTL•Autolus Therapeutics will present ASCO data showing obe-cel achieved a 59% overall response rate and 42.6-month median duration of response in B-ALL patients with extramedullary disease. The post-hoc FELIX Phase Ib/II analysis included 27 of 127 infused adults with EMD, demonstrating favorable benefit-risk in this high-risk group.
1. Clinical Data Highlights
The post-hoc analysis of the FELIX study evaluated obe-cel in 127 adults with relapsed/refractory B-ALL, including 27 patients with extramedullary disease. The therapy achieved an overall remission rate of 59% and a median duration of response of 42.6 months in the EMD subgroup, indicating durable activity in this high-risk population.
2. FELIX Study Design
In the Phase Ib/II FELIX trial (NCT04404660), adults received obe-cel following lymphodepletion using a tumor burden-guided dosing strategy to minimize toxicity. The analysis compared efficacy and safety outcomes between patients with and without EMD at lymphodepletion, with favorable benefit-risk observed across both cohorts.
3. ASCO Presentation Logistics
The data will be presented as Rapid Oral Abstract 6517 in the Hematologic Malignancies session on May 30, 2026, from 1:15 to 2:45 PM CDT in room E450a, with a specific presentation slot at 2:27 PM by Jae Park, MD.
4. Autolus Therapeutic Pipeline
Autolus, a commercial-stage biopharmaceutical company, markets AUCATZYL and develops next-generation T cell therapies for hematological malignancies and autoimmune diseases using proprietary modular programming technologies. Ongoing pipeline candidates include treatments targeting solid tumors and additional blood cancers.
